Carderock Capital Management
LLY icon

Carderock Capital Management’s Eli Lilly LLY Stock Holding History

Carderock Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.7M Sell
12,679
-139
-1% -$164K 3.37% 6
2026
Q2 		$15.4M Buy
12,818
+236
+2% +$241K 3.37% 4
2026
Q1 		$11.6M Buy
12,582
+398
+3% +$403K 2.86% 7
2025
Q4 		$13.1M Buy
12,184
+1,022
+9% +$977K 3.17% 5
2025
Q3 		$8.52M Buy
11,162
+121
+1% +$90K 2.07% 17
2025
Q2 		$8.61M Buy
11,041
+1,581
+17% +$1.23M 2.2% 18
2025
Q1 		$7.81M Buy
9,460
+1,337
+16% +$1.11M 2.07% 24
2024
Q4 		$6.27M Sell
8,123
-848
-9% -$702K 1.57% 36
2024
Q3 		$7.95M Buy
8,971
+1,206
+16% +$1.08M 1.88% 25
2024
Q2 		$7.03M Buy
+7,765
New +$6.21M 1.84% 30
2023
Q2 		– Sell
-185
Closed -$63.5K – 90
2023
Q1 		$63.5K Buy
+185
New +$62.4K 0.02% 93

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Carderock Capital Management's LLY Position: Q3 2026 in Review

Carderock Capital Management reduced its Eli Lilly (LLY) stake by 1.1% in Q3 2026, selling an estimated $164K and leaving 12,679 shares worth $14.7M. The position accounts for 3.37% of the portfolio, ranked #6.

Carderock Capital Management first reported a position in LLY in Q1 2023 and has held it in 11 quarters since. The position peaked at $15.4M in Q2 2026. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Carderock Capital Management held 12,679 shares of Eli Lilly worth $14.7M as of Q3 2026.
  • Carderock Capital Management sold 139 Eli Lilly shares in Q3 2026, an estimated $164K.
  • Eli Lilly made up 3.37% of Carderock Capital Management's portfolio in Q3 2026, its #6 holding.
  • Carderock Capital Management first reported a position in Eli Lilly in Q1 2023 and has held it in 11 quarters since.
  • Carderock Capital Management's Eli Lilly position peaked at $15.4M in Q2 2026.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Carderock Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.